ASAM eLearning
Catalog Advanced Search
-
Webinar: The ASAM Criteria Copyright and Permissions Process for Providers
Contains 1 Component(s)In this free webinar, learn about the ASAM Criteria copyright and permissions process for providers.
Webinar Overview
In Spring 2019, The ASAM Criteria copyright and permissions process was updated to include agreements to enable public entities, providers, and other stakeholders to reference their use of The ASAM Criteria. The changes are part of a range of programs designed to support effective implementation of The ASAM Criteria and protect ASAM’s intellectual property from misuse. These programs include an ASAM Level of Care certification program delivered by CARF, a robust training program on The ASAM Criteria, and ongoing enhancements to the ASAM CONTINUUM software – a clinical decision support tool used to assist in treatment planning for individuals with addiction. All of these initiatives have the end goals of protecting patients and preserving the credibility of providers accurately implementing the evidence-based standards found in The ASAM Criteria.
Margaret A.E. Jarvis
MD, DFASAM
Margaret Jarvis finished her medical school, psychiatry residency and Addiction Medicine Fellowship at the Medical College of Virginia in Richmond. She is board certified and recertified in psychiatry with the CAQ in Addiction Psychiatry. She was ASAM certified (now ABAM certified). She has been a member of ASAM since the early 90’s and became a Fellow of the Society in 2003. She has served on the Board of Directors for one term and currently is the co-chair of the Ruth Fox Planning; and a member of the Finance Committee and the Constitution and Bylaws Committee. She has also worked on Examination Committee for ASAM and now ABAM since 2000.
Dr. Jarvis is the Medical Director at Marworth, in Waverly, PA, which is the residential addiction treatment center for the Geisinger Health System. She has been in this position since 1999. She is also Clinical Assistant Professor of Psychiatry at the Penn State University College of Medicine in Hershey, PA.
Dr. Jarvis is a member of the Society for the Advancement of Sexual Health, a professional organization of therapists who treat sexual addiction, and served on that board of directors from 2001-2006, as president from 2004-2006. She received the Merit award from SASH in 2011. Dr. Jarvis currently serves as the Treasurer of the Board of Marley’s Mission, a non-profit that provides equine-assisted psychotherapy to abused children in the Scranton, PA area.
-
Webinar: What is ASAM Level of Care Certification?
Contains 1 Component(s)In this free webinar, learn about the ASAM Level of Care certification and the pilot process that was used to ensure its validity.
Webinar Overview
This webinar provides an overview of ASAM Level of Care certification and the pilot process that was used to ensure its validity. ASAM Level of Care certification, delivered in partnership with CARF International, is the first program of its kind to independently assess and verify treatment programs’ ability to deliver services consistent with the levels of care described in The ASAM Criteria. It will initially cover adult residential programs at Levels 3.1, 3.5, and 3.7 of The ASAM Criteria. The certification demonstrates a program’s capacity to deliver a specific level of care, thereby differentiating between the many levels of care available for addiction treatment.
Paul H. Earley
MD, DFASAM
Dr. Earley has worked in Addiction Medicine for over 30 years. He treats all types of addictive disorders and specializes in the assessment, treatment and management of health care professionals. As a therapist, he works with patients already in recovery, providing long term therapy for those who suffer from this disease. His professional expertise extends to advocacy for professionals before agencies and licensing boards.
Dr. Earley is a dynamic speaker and educator; he speaks and trains on topics of addiction, its treatment and addiction among health care professionals. In addition, he trains therapists about the neurobiological basis of psychotherapy. In his travels, he has provided training in the United States, Canada, the United Kingdom, Italy, Iceland and Switzerland.
He is the author of two books and several research articles on addiction and its treatment. His most recent book, RecoveryMind Training is an innovative and comprehensive process designed to reengineer addiction treatment. He is a contributing author to the American Society of Addiction Medicine (ASAM) Textbook: Principles of Addiction Medicine, as author of the chapter: Physician Health Programs and Addiction among Physicians. He is a contributing author to the ASAM Criteria. His work was featured in the documentary series on addiction entitled Close to Home by Bill Moyers.
Currently, Dr. Earley is the Medical Director of the Georgia Professionals Health Program, Inc., the Physicians Health Program (PHP) for the state of Georgia and the President-elect of the Federation of State Physician Health Programs (FSPHP). Dr. Earley is the current president-elect of the American Society of Addiction Medicine (ASAM). He is a Distinguished Fellow of ASAM and has served on the board of ASAM for over 14 years in several capacities.
Michael W. Johnson
MA, CAP
Michael joined CARF as managing director of the Behavioral Health accreditation area in 2013. A certified addictions professional, Michael has more than 30 years of experience as a clinician, manager, and executive working in mental health, substance abuse, and intellectual disabilities. He was a CARF surveyor for 16 years and holds a master's degree in communications from the University of Central Florida.
-
ASAM 50th Annual Conference - Innovations in Addiction Medicine and Science - 2019 (85 CME)
Contains 63 Product(s)Earn a maximum of 85 AMA PRA Category 1™ credits while learning about the latest innovations in Addiction Medicine and Science from these on-demand conference recordings from the nation’s premiere conference on the latest science, research, best practices and innovations in addiction medicine.
Overview
The ASAM Annual Conference is the nation’s premiere event showcasing best practices and the latest science, research, and innovations in addiction medicine. View over 60 high-quality educational sessions on a variety of topics to address your educational needs!
Learning Objectives
At the conclusion of this activity, participants should be able to:
- Identify and describe the new developments affecting the science, policy, and clinical practice of addiction medicine.
- Compare presented clinical guidelines/best practices with the participant's current practice and identify strengths or gaps.
- Analyze new research and science to develop practical applications for treatment or further research.
- Explain recent or upcoming policy changes and identify implications or areas for provider involvement.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 85 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 85 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 85 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 85 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Who Should Attend
Healthcare professionals dedicated to increasing access and improving the quality of addiction treatment and care, including:
- Physicians and Clinicians
- Researchers and Academics
- Students and Retirees
- Counselors and Policymakers
-
Overdose Fatality Reviews: A Data-Driven Collaboration (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning about the structure and process of overdose fatality reviews. from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn:
Overdose fatality reviews allow communities to examine and understand the circumstances surrounding fatal drug overdoses. Review teams can uncover the individual and population factors and characteristics of potential overdose victims. Knowing the who, what, when, where, and how of fatal overdoses provides a better sense of the strategies and coordination needed to prevent future overdoses and results in the better allocation of overdose prevention resources and services. This session will provide an overview of overdose fatality review and highlight successes and challenges in the field from local, state and tribal perspectives. Funding and training and technical assistance opportunities through Bureau of Justice Assistance will be highlighted. There will be a panel of four individuals and the session will include funding and training opportunities from the Bureau of Justice Assistance, an overview of the structure and process of an overdose fatality review, a state level view of the OFR model and features in Wisconsin, and a local level view in Prince George County Maryland. Tara L. Kunkel
MSW
Tara Kunkel is presently on detail to the Department of Justice, Bureau of Justice Assistance through an interagency agreement serving as a Senior Drug Policy Advisor. Ms. Kunkel oversees BJA’s prescription drug monitoring program as well as the Comprehensive Opioid Abuse Program. Ms. Kunkel graduated from Virginia Commonwealth University with a Masters in Social Work and received her BA in Psychology from the University of Virginia. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Up in Smoke: Igniting Recovery from Tobacco and e-Cigarettes (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 PRA Category 1 Credit(s)™ while learning how to improve nicotine and tobacco research from this conference recording from The ASAM 50th Annual Conference (2019).
1.5 CME In this conference recording from the 2019 Annual Conference, you will learn that:
Historically, substance use disorder treatment centers have only offered limited-to-no treatment for tobacco dependence during their programs. Over the last 30 years, significant gains have been made in behavioral management for tobacco dependence, FDA approval of 7 medications, development of outpatient and inpatient treatment protocols, and the establishment of tobacco-free hospitals and behavioral treatment centers. In addition, tobacco price elasticity, increased public health knowledge of risks, restrictions in tobacco marketing, and clean, indoor-air laws have resulted in lower tobacco consumption in the general population. However, these gains have not had enough impact to lower the rates of tobacco-related chronic health diseases in individuals with substance use disorders. Tobacco use is the number one cause of death for people with alcoholism1 . Furthermore, there are potential threats to the advances already made, including the rapid acceptance of electronic nicotine delivery systems (ENDS) within the last 10 years and the decriminalization and/or legalization of recreational or medical of cannabis use in 30 states over the past two decades. The increasing awareness of tobacco-related, chronic disorders amongst both the public and medical professionals presents an opportune climate for improving the screening and treatment of tobacco dependence in patients receiving treatment for other addictions. Four potential opportunities include:
1) Dissemination of an increasing number of novel, evidenced-based protocols specifically for individuals with tobacco and co-occurring substance use disorders; 2) Recognition by medical and behavioral health providers of patient satisfaction and improved outcomes when tobacco is addressed during addiction therapy; 3) Identification, training and collaboration of addiction specialists to advance this concept; and 4) Awareness of the potential use of ENDS to intentionally deliver other drugs of abuse and need for education of patients and staff about impact of ENDS products on long-term recovery. This workshop will offer best practices of current evidence-based protocols and provide tools for creating effective treatment options that can be applied in a variety of settings. The participants will engage in small group, interactive exercises that will develop action plans for addressing tobacco-use disorders within their own treatment settings and on a national level. Outline: Review important historical milestones in efforts to treat tobacco dependence in addiction settings Discuss potential threats for gains already made in the treatment of tobacco dependence over two decades Discuss potential opportunities and challenges to improve the treatment of tobacco dependence for recovering populations Each participant will be empowered to develop a personalized Strengths, Weakness, Opportunities and Threats (SWOT) analysis of their program during the workshop.Learning Objectives:
Upon completion, participant will be able to:
Develop 3 novel and effective strategies for improving nicotine and tobacco treatment research, reimbursement, and service delivery.
Lori D. Karan
MD, DFASAM, FACP
Lori Karan, MD, DFASAM, FACP is Professor of Internal Medicine and Preventive Medicine and Director of the Addiction Medicine Fellowship at the Loma Linda University Medical School. She works in the Substance Treatment and Recovery (STAR) program of the Loma Linda VA Healthcare System (LLVAHCS). During her internal medicine training, Dr. Karan repeatedly treated patients for the consequences of tobacco use. She recognized that nicotine and tobacco use were often ignored during the treatment of other substance use disorders and that tobacco was the number one cause of death in recovering persons.
Dr. Karan guest-edited a seminal issue of the Journal of Substance Abuse Treatment entitled “Towards a Broader View of Recovery.” These experiences set the foundation for Dr. Karan’s longstanding interest in in the similarities and differences between nicotine and other addictive drugs. Dr. Karan advocated for tobacco control, including befriending the Phillip Morris whistleblower scientists and putting forth stockholder’s proposals during annual meetings of Phillip Morris, and RJ Reynolds. She received a NIDA Scientist Development Award where she researched the discriminative stimulus effects and neuroendocrine basis for the subjective effect of nicotine.
Dr. Karan and John Rosecrans PhD co-chaired nine annual ASAM Nicotine Research Round tables and from this excitement originated the Society for Research on Nicotine and Tobacco. More recently Dr. Karan and Dr. Susan Blank authored the Nicotine and Tobacco chapter of the ASAM Criteria where they advocated for increased intensity of treatment for persons who had severe nicotine/tobacco use disorders, medical, and/or psychiatric co-morbidity. Dr. Karan was recruited to LLVAHCS by Dr. Linda Ferry, originator of Zyban. Dr. Ferry and Dr. Karan continue to develop effective treatments for nicotine and tobacco use, especially in patients who have other substance use disorders. 1 Hurt RD et al. “Mortality following inpatient addictions treatment.” JAMA 1996 Apr 10; 275(14):1097-1103.Laura Martin
MD, FASAM
Laura F. Martin, M.D. is an Associate Professor of Psychiatry at the University of Colorado School of Medicine. She is a board certified psychiatrist and addiction medicine specialist. She has been recognized as a member of the American College of Psychiatrists, a Fellow of the American Society of Addiction Medicine, and a Distinguished Fellow of the American Psychiatric Association. Her professional roles include serving as the Medical Director of the Center for Dependence, Addiction and Rehabilitation (CeDAR), Program Director of the Addiction Medicine Fellowship at the University of Colorado School of Medicine, and as President of the Colorado Society of Addiction Medicine. She regularly works with individuals with both substance use disorders and other behavioral health disorders to improve their physical and mental health and has published peer reviewed research and clinical reviews regarding this work.
Linda Hyder Ferry
MD, MPH
Chad D. Morris
PhD
Chad Morris, Ph.D. is a Professor of Psychiatry at the University of Colorado- School of Medicine, and Director of the Behavioral Health & Wellness Program. He is the principal investigator of many projects and studies exploring the effectiveness of organizational, psychosocial, and pharmacologic wellness and tobacco cessation strategies. As the Vice President of Spark Inspiration, Dr. Morris also offers corporate wellness solutions. He has worked with over 40 states to foster sustainable whole health and tobacco control initiatives for priority populations including persons with mental illnesses, addictions, and justice involved individuals. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Expanding Access to Buprenorphine for Justice-Involved Individuals via Mobile Treatment (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to expand access to MAT for justice-involved individuals from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:
Opioid use disorder (OUD) is highly prevalent among justice-involved individuals. Despite evidence that increasing access to medications for addiction treatment (MAT) decreases fatal overdoses after release from prison and jail, many barriers to expanding treatment for this population remain. Most interventions to date have focused on expanding access to MAT inside the criminal justice system, which can work well for those serving longer sentences in prisons, but the high turnover in jails and pre-trial detention centers is not always amenable to starting MAT inside jail.
In this interactive panel discussion, we will describe the development of Project Connections to Re-Entry (PCARE), a novel treatment model to expand access to buprenorphine for justice-involved individuals. Started in November 2017, PCARE is part of a network of low-threshold buprenorphine treatment site run by Behavioral Health Leadership Institute (BHLI). PCARE provides access to low threshold MAT through a mobile van parked directly outside the Baltimore City Jail in partnership with Maryland Department of Public Safety and Correctional Services. Patients are referred by jail staff or can walk in from the street. The clinical team includes an experienced primary care physician who prescribes buprenorphine, a nurse, and a peer recovery coach. Once stabilized, patients are transitioned to longer-term treatment programs or primary care for buprenorphine maintenance.
Between November 2017 and July 2018, 249 people approached the van, 127 of whom began treatment with buprenorphine-naloxone. The majority of patients (94.4%) had previous criminal justice involvement, were unemployed (72.4%) and were living with family or friends (41.7%). Of those who began treatment, 67.7% returned for a second visit or more, and 29% percent were still involved in treatment after 30 days. This focus session will begin with brief overview of current literature regarding access to MAT in criminal justice settings. The interdisciplinary panel, composed of the program director (a lawyer) and physicians, will then describe the process of developing this program, client characteristics and initial outcomes, and implications for expansion to other treatment settings.
The panel will discuss successes and challenges in partnering with detention center staff and engaging vulnerable populations in care. After the panel discussion, the group will break into small groups to discuss ways of expanding access to buprenorphine in their own settings. There will be time at end for Q+A. Proposed Timeline (in minutes): 0:00 �" 0:10 Brief review of literature related to MAT in criminal justice setting and mobile treatment models 0:10 �" 0:55 Panel discussion of PCARE low-threshold buprenorphine model 0:55 �" 1:10 Breakout into small groups to discuss expanding treatment in their own settings 1:10 �" 1:30 Questions and Answers/Session EvaluationLearning Objectives:
1.) Describe current literature on MAT for justice-involved populations.
2.) Describe a model of low threshold buprenorphine treatment for justice-involved individuals
3.) Identify ways to partner with criminal-justice settings and expand access to MAT for justice-involved individuals in their own geographic area
Megan Buresh
MD
Dr. Megan Buresh is an Assistant Professor of Medicine and Epidemiology at the Johns Hopkins University School of Medicine. She is board certified in internal medicine and addiction medicine and certified as AAHIVM HIV Specialist. She received a Bachelor of Arts in Biochemical Sciences from Harvard University (magna cum laude with highest honors in field), completed medical school at Johns Hopkins University School of Medicine and residency at Brigham and Women’s Hospital. She is the Secretary of the Maryland-DC ASAM Chapter. She is medical director of the Johns Hopkins Bayview Inpatient Addiction Consult Service. She also provides integrated buprenorphine treatment as part of her outpatient primary care practice. She is lead physician for BHLI PCARE, a mobile buprenorphine clinic for patients being released from Baltimore City Jail. Her research interests include public health and addiction, developing and evaluating models to expand office-based opioid treatment, and improving linkages between clinical addiction treatment and community organizations. She is a co-investigator with the ALIVE study at the Johns Hopkins Bloomberg School of Public Health, where she is studying risk factors for opiate overdose and access to naloxone among persons who inject drugs. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
The World of Weird Withdrawal (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal. from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:
With changing patterns of opioid use, a growing number of patients are at risk for experiencing opioid withdrawal. Due to convenient access to “pseudo-medical” information via social media and purchasing options on the Internet, patients may be using a variety of substances to “self-detox” or to mitigate withdrawal symptoms at home, such as kratom, ibogaine, and loperamide, all of which have potentially toxic effects. Treatment and recovery providers need to be knowledgeable of how patients self-treat opioid withdrawal, and to understand and manage the complications that arise from such practices. Additionally, patients may present with precipitated withdrawal from buprenorphine, naltrexone, or well-intended naloxone administration. These periods of intense withdrawal place patients at risk for medical complications and can jeopardize the early stages of recovery. Understanding the risks and optimizing management using opioid and non-opioid strategies can comfort patients and improve treatment engagement. This session is an interactive case-based workshop in which clinicians will discuss strategies to manage patients with atypical or unusually severe presentations related to opioid self-detoxification and precipitated withdrawal. Cases will illustrate the expected and unintended consequences related to the use of loperamide, kratom, and ibogaine as agents of self-detoxification. Attendees will develop approaches to diagnose and manage the complications of these so-called “alternative” detoxification agents, and learn to identify and treat the withdrawal that develops after regular use of kratom. We will also review the pathophysiology of precipitated withdrawal, discuss strategies to prevent this complication, and examine options to manage severe withdrawal. As there is currently no consensus on the best practices for treating atypical or complex opioid withdrawal, this session will offer an in-depth look at the benefits, risks, and knowledge gaps in rapid buprenorphine induction after naloxone- or naltrexone-precipitated withdrawal, and evaluate the use of other evidence-based agents such as opioid agonists, alpha-2 agonists, gabapentin, and atypical antipsychotics for patients with these multifaceted opioid withdrawal syndromes. Learning Objectives:
1.) Recognize the toxic syndromes that result from strategies patients use to self-treat opioid withdrawal.
2.) Discuss the varied clinical presentation and management of patients with atypical or complex opioid withdrawal.
3.) Identify methods to minimize the risk of and manage precipitated withdrawal from opioid antagonists or partial agonists.
Aliana R. Steck
MD
Dr. Alaina Steck is a graduate of the Keck School of Medicine at the University of Southern California, did her residency training in Emergency Medicine at Boston Medical Center, and completed fellowship at the Emory University / Centers for Disease Control and Prevention Joint Fellowship in Medical Toxicology. She is board-certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine, and practices all three clinical specialties at Grady Memorial Hospital in Atlanta, Georgia. She serves as an assitant medical director at the Georgia Poison Center and the medical director of the Grady Medication-Assisted Opioid Treatment clinic. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Enhancing Motivation, MAT Adherence & Retention with Routine Use of Contingency Management (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to describe the foundation for enhanced treatment outcomes in SUD patients using contingency management from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that Contingency Management (CM) is the best-researched, most effective -- yet least utilized -- treatment innovation in addiction. After a half-century of research, clinicians still have numerous concerns: ethics (is it enabling to pay patients money?), resources (where will the money come from?), testing (frequent and visually witnessed drug testing?) & management (who will do the intricate accounting?). Technology can surmount each of these obstacles, with the added plus of patient engagement & relapse/dropout prediction. Providers will describe technology's potential for enhancing motivation, improving MAT adherence, & extending treatment retention. Data from thousands of patient events with several different technologic tools indicates that these approaches are feasible with many types of: Substance use disorders (from tobacco smoking to opioids) Subpopulations (from pregnant women to criminal justice-involved returning citizens to corporate executives) Providers (from counselors to case managers to recovery coaches), and Settings (from medical centers to recovery homes to national insurance companies). Finally, large data (e.g., < 90,000 financial transaction events from 1,400 patients) can generate imminent dropout and relapse indicators with good validity (e.g., 70% positive predictive value) that can be used to issue real-time alerts to providers to intervene -- even prior to a patient's return to drug use, allowing rapid treatment intensification without the need for repeat detoxification to address withdrawal. Impacts range from decreased drinking, to longer treatment retention to meaningful program completion (e.g., improving graduation rates from 67% to 87% within a justice-system involved long-term rehabilitation). Attendees will workshop how to achieve practical implementation within busy, oversubscribed and scarcely-resourced practices and treatment programs in the midst of an epidemic.
Learning Objectives:
1.) Explain the obstacles that have prevented wide-spread adoption of contingency management in routine care.
2.) Describe the research foundation for enhancing treatment outcomes in patients with substance use disorders using contingency management.
3.) Analyze the utility of various new technologies that have been proposed and implemented to overcome the obstacles to adoption of contingency management.
David Gastfriend
MD, DFASAM
David R. Gastfriend, MD, served on the faculty of Harvard Medical School for 25 years, most recently as Director of the Addiction Research Program at Massachusetts General Hospital (MGH). His studies of the Patient Placement Criteria published by the American Society of Addiction Medicine (ASAM) have been supported by the NIH's National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Alcoholism, the U.S. Centers for Disease Control, U.S. state governments, managed care corporations, including Aetna Behavioral Healthcare, and foreign governments, including Belgium, Finland, Iceland, Israel, Norway, Switzerland, and the World Health Organization. The author of over 125 scientific publications, he has served on the Boards and Editorial Boards of a number of societies and journals, including ASAM and the International Society of Addiction Medicine (ISAM). He is co-editor of the leading book on treatment matching in the field, The ASAM Patient Placement Criteria for Substance-Related Disorders and editor of Addiction Treatment Matching. In addition to his role at RecoverySearch, Dr. Gastfriend is also Vice President for Scientific Communications at Alkermes, Inc. (NASDAQ: ALKS) where he is involved in research, education and scientific publication on extended-release naltrexone (VIVITROL®) and the company's efforts in the field of addiction treatment.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Opening Scientific Plenary & Distinguished Scientist Lecture (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to understand and mitigate risk factors leading up to drug use from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that:
The Special ASAM 50th Annual Conference begins with an energizing Opening Scientific Plenary Session and highlights from the past 50 years. Moderated by ASAM President Kelly J. Clark, MD, MBA, DFAPA, DFASAM, distinguished presenters of the opening session will focus on incredible cutting-edge science in addiction medicine and a new paradigm of hope for prevention and treatment. Nora D. Volkow, MD Science Advances in the Prevention and Treatment of Opioid Addiction The misuse of and addiction to opioids"including prescription pain relievers, heroin, and synthetic opioids such as fentanyl"has resulted in a national crisis that we have not yet been able to revert. This presentation will highlight how NIH researchers are using scientific advances being made to turn the tide in the opioid crisis through the development of: new medications to treat pain; innovative drug abuse prevention strategies that can mitigate an individual’s vulnerability to addiction; and promising strategies that can successfully treat opioid use disorder and prevent and reverse overdose. Bankole Johnson Personalizing the Treatment for Alcohol Use Disorders This presentation will characterize the development of a genetic-based treatment for alcohol use disorders from animals to humans as well as prospects for regulatory approval. What is the genetic loading for alcohol use disorder? What is an inverted U-shaped dose curve? What is the frequency of the target genetic cohort for the treatment of alcohol use disorders? David & Nic Sheff A New Paradigm Facing America's Drug Use and Addiction Crises We're in crisis, but there's hope. The hope is a new paradigm for preventing and treating drug use and addiction in America. For prevention, we focus on drugs, but the key to prevention is a recognition of why people use them--understanding and mitigating risk factors. For treatment: We're at the beginning of a sea change as we reject failed efforts of the past -- ones based on the view that addiction is a choice -- and replace it with one based on the science of addiction medicine. We've a long way to go at a time we're losing more people under 50 from overdose than anything else. But we have a roadmap. ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
-
Designer Drugs Update 2019: Phenibut, Synthetic Opioids, & More (1.5 CME)
Contains 4 Component(s), Includes CreditsEarn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use from this conference recording from The ASAM 50th Annual Conference (2019).
(1.5 CME) In this conference recording from the 2019 Annual Conference, you will learn that/about:
Learning Objectives:
1.) Identify emerging designer drugs, including phenibut, synthetic opioids, and others.
2.) Recognize clinical clues to intoxication with emerging designer drugs, and ways to differentiate from other drug use.
3.) Discuss treatment of medical and psychiatric complications resulting from use of designer drugs.
Patterns of drug abuse are constantly changing. This is particularly the case regarding new psychoactive substances or designer drugs, in which new variants are continually emerging with uptake especially among young adults. New synthetic designer drugs can be challenging to identify and treat effectively, especially serious medical and psychiatric complications. This is important for practitioners, as new designer drugs have resulted in multiple deaths, as well as other significant health consequences to users. This session will educate practitioners about several newer designer drugs regarding use trends along with psychotropic and health effects. Session description: This focus session will inform attendees with a discussion�"including clinical case examples�"that will focus on emerging designer drugs, including phenibut, synthetic opioids, and others. Use of these drugs has caused significant medical and psychiatric consequences, including multiple deaths, which has received recent media attention. The presentation will be evidence-based and draw from existing medical literature, and will also include the panelists’ clinical experience with patients experiencing designer drug use and complications. The emphasis will be on clinical issues, especially recognition of intoxication, problems related to detection with urine drug testing, and treatment of medical and psychiatric complications. Attention will be given to specific populations that have been shown to be using these designer drugs. The presenters are experienced clinicians who have been involved in evaluation of patients using designer drugs. The presenters have also published about designer drugs in peer-reviewed journals. Attendees will be able to share their own experiences with patient use of designer drugs to enrich the discussion. Time will be allowed for questions to the panelists so that there will be significant interaction during this focus session. Conclusions: This focus session will provide attendees with evidence-based clinical knowledge to help identify and treat complications from newer designer drug use, especially those with life-threatening complications. Michael F. Weaver
MD, DFASAM
Dr. Michael Weaver is Professor of Psychiatry and Medical Director of the Center for Neurobehavioral Research on Addiction at The University of Texas McGovern Medical School at Houston. He completed a Residency in Internal Medicine and a Clinical Research Fellowship in Addiction Medicine at Virginia Commonwealth University. He is involved in patient care, medical education, and research. Dr. Weaver has multiple publications in the field of addiction medicine. He treats patients at the Innovations Addiction Treatment Clinic at the Texas Medical Center in Houston, which provides medication-assisted treatment. He is the Sub-Board Chair for Addiction Medicine for the American Board of Preventive Medicine. He is a member of the ASAM Publications Council and on the Editorial Board for the Journal of Addiction Medicine.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.
ABIM Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
